The rearranged during transfection (RET) proto-oncogene was identified in 1985 and, very
soon thereafter, a rearrangement named RET/PTC was discovered in papillary thyroid …

Genetic alteration is the driving force for thyroid tumorigenesis and progression, based upon
which novel approaches to the management of thyroid cancer can be developed. A recent …

The variety of diseases caused by mutations in RET receptor tyrosine kinase provides a
classic example of phenotypic heterogeneity. Gain-of-function mutations of RET are …

According to the literature thyroid nodules are quite rare in the first two decades of life.
However, there are some exceptions, relating to areas with an iodine deficiency or affected …

Background: Medullary and papillary thyroid carcinomas are often associated with
oncogenic activation of the RET tyrosine kinase. We evaluated whether the biaryl urea BAY …

The RET proto-oncogene encodes a receptor tyrosine kinase for the glial cell line-derived
neurotrophic factor family of ligands. Loss-of-function mutations in RET are implicated in …

Six multiple endocrine neoplasia (MEN) syndromes have received a level of attention that
might seem disproportionate to their low prevalence. The attention has been given because …

Multiple endocrine neoplasia type 2 is historically composed of three clinical subtypes, all of
which are associated with germline mutations in the RET proto-oncogene. Multiple …

Abstract Multiple Endocrine Neoplasia type 1 (MEN1) is a rare autosomal dominant
hereditary cancer syndrome presented mostly by tumours of the parathyroids, endocrine …

Medullary thyroid carcinomas (MTC) arise from thyroid parafollicular, calcitonin-producing C-
cells and can occur either as sporadic or as hereditary diseases in the context of familial …